Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Toru Ikegami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5792-5045; OpenAlex author ID A5056881700, A5124954984. Sources: OpenAlex.

Their work

Papers
46 (first author 0, last author 38)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 6 papers · 2022: 5 papers · 2023: 6 papers · 2024: 5 papers · 2025: 9 papers · 2026: 9 papers

Papers 46

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. Last author DOI 10.1002/wjs.70666↗
  2. The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer. Last author DOI 10.1007/s00595-025-03188-7↗
  3. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Last author DOI 10.1007/s00595-026-03344-7↗
  4. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Last author DOI 10.1007/s00595-026-03416-8↗
  5. Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. Co-author DOI 10.1016/j.ebiom.2026.106137↗
  6. Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-026-20340-w↗
  7. ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-026-20399-5↗
  8. Sialic Acid-Fibronectin-negative and CD-44-positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition. Last author DOI 10.21873/anticanres.17965↗
  9. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Last author DOI 10.21873/cdp.10600↗
  10. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. Last author DOI 10.1007/s00595-024-02882-2↗
  11. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Last author DOI 10.1007/s00595-025-03050-w↗
  12. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Last author DOI 10.1007/s00595-025-03088-w↗
  13. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Last author DOI 10.1016/j.suronc.2024.102179↗
  14. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Last author DOI 10.1016/j.suronc.2025.102270↗
  15. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002416↗
  16. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Last author DOI 10.1177/00031348241272420↗
  17. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Last author DOI 10.1177/00031348241278016↗
  18. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Last author DOI 10.1177/00031348241278021↗
  19. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00423-024-03315-x↗
  20. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Last author DOI 10.1016/j.pan.2024.01.003↗
  21. The prognosis-based classification model in resectable pancreatic cancer. Last author DOI 10.1016/j.suronc.2024.102035↗
  22. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.16968↗
  23. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Last author DOI 10.21873/anticanres.17229↗
  24. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Last author DOI 10.1007/s00520-023-08206-3↗
  25. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Last author DOI 10.1016/j.suronc.2023.101998↗
  26. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1177/00031348231204912↗
  27. Successful resection of port site recurrence of pancreatic ductal adenocarcinoma after laparoscopic distal pancreatectomy. Last author DOI 10.1186/s40792-023-01607-w↗
  28. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Last author DOI 10.21873/anticanres.16150↗
  29. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Last author DOI 10.21873/anticanres.16599↗
  30. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Last author DOI 10.1007/s00423-022-02686-3↗
  31. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Last author DOI 10.1007/s12032-021-01625-4↗
  32. Usefulness of the mesopancreas-first approach using isolating tape in conversion surgery for pancreatic cancer. Last author DOI 10.1016/j.suronc.2022.101850↗
  33. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. Last author DOI 10.1093/carcin/bgac060↗
  34. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Last author DOI 10.1371/journal.pone.0267623↗
  35. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. Last author DOI 10.1002/ags3.12447↗
  36. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… Last author DOI 10.1007/s00423-021-02166-0↗
  37. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Last author DOI 10.1007/s10147-021-01964-2↗
  38. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer. Last author DOI 10.1007/s10147-021-01986-w↗
  39. Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer. Co-author DOI 10.1111/cas.14921↗
  40. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Last author DOI 10.1111/cas.15123↗
  41. Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04324-8↗
  42. Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.011↗
  43. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2019.02.038↗
  44. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Co-author DOI 10.1002/cam4.1087↗
  45. Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patients. Co-author PMID 27127150↗
  46. Giardiasis in the pancreas accompanied by pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3181f6a1b9↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Shirai · 35 shared papers, 2021–2026 · strength 7.01
  2. Kenei Furukawa · 33 shared papers, 2021–2026 · strength 6.83
  3. Koichiro Haruki · 29 shared papers, 2021–2026 · strength 6.15
  4. Shinji Onda · 25 shared papers, 2021–2026 · strength 5.09
  5. Masashi Tsunematsu · 23 shared papers, 2022–2026 · strength 5.07
  6. Michinori Matsumoto · 19 shared papers, 2021–2026 · strength 4.19
  7. Takeshi Gocho · 19 shared papers, 2021–2026 · strength 3.78
  8. Ryoga Hamura · 21 shared papers, 2021–2026 · strength 3.76
  9. Mitsuru Yanagaki · 15 shared papers, 2021–2026 · strength 3.26
  10. Tomohiko Taniai · 13 shared papers, 2021–2026 · strength 2.56
  11. Norimitsu Okui · 10 shared papers, 2023–2026 · strength 2.30
  12. Yoshiaki Tanji · 10 shared papers, 2023–2026 · strength 2.29
  13. Tadashi Uwagawa · 12 shared papers, 2021–2026 · strength 2.12
  14. Kyohei Abe · 9 shared papers, 2021–2025 · strength 1.68
  15. Taro Sakamoto · 8 shared papers, 2022–2026 · strength 1.65
  16. Yosuke Igarashi · 7 shared papers, 2023–2026 · strength 1.61
  17. Tadashi Uwagawa · 5 shared papers, 2024–2025 · strength 1.19
  18. Yuta Yamada · 4 shared papers, 2024–2026 · strength 1.01
  19. Shuichi Fujioka · 5 shared papers, 2022–2025 · strength 0.92
  20. Hironori Shiozaki · 5 shared papers, 2021–2024 · strength 0.85
  21. Shunta Ishizaki · 3 shared papers, 2023–2025 · strength 0.63
  22. Takashi Horiuchi · 5 shared papers, 2021–2022 · strength 0.63
  23. Takashi Aida · 2 shared papers, 2023–2026 · strength 0.46
  24. Hiroaki Shiba · 3 shared papers, 2021–2022 · strength 0.40
  25. Tomoharu Yoshizumi · 5 shared papers, 2016–2020 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.